Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation
Authors:
- 20 February 2019
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 42 (3) , 369-380
Abstract
Hepatocellular carcinoma (HCC) is an aggressive malignancy. In HCC, mitogen-activated protein kinase (MAPK) signaling is overactivated. The MAPK kinase (MEK) inhibitor trametinib has been approved to treat several types of advanced cancers with a BRAF mutation. Herein, we examined whether trametinib has efficacy against HCC.Keywords
Funding Information
- National Natural Science Foundation of China (81301141, 81100274 and 81570522)
- Natural Science Foundation of Jiangsu Province (BK20131387)
- the Priority Academic Program Development of Jiangsu Higher Education Institutions
This publication has 39 references indexed in Scilit:
- S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathwayInternational Journal of Oncology, 2013
- Targeting MYC dependence in cancer by inhibiting BET bromodomainsProceedings of the National Academy of Sciences, 2011
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- Differences underlying EGFR and HER2 oncogene addictionCell Cycle, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007